HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk PatientsHOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients

Alone or with blood-pressure-lowering therapy, at least in those with elevated baseline BP, rosuvastatin lowered composite end points by 24% to 29% vs placebo. Heartwire from Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news